What Does the EBO2 (EBOO) Filter Actually Remove?

EBO2 (also called EBOO) clinics routinely describe the procedure as removing toxins, cholesterol, heavy metals, and inflammatory material from the blood; the pillar guide on what EBO2 is covers the rest of the procedure. Those are specific, testable claims, and the peer-reviewed record on EBOO does not test most of them. This guide walks through what the filter is built from, what has actually been measured about what passes through it, and why a visibly dirty filter is not, on its own, proof of anything in particular.

The claims

One clinic FAQ describes the mechanism as a “dual-action mechanism” in which “the filtration system physically traps heavy metals, fats, and inflammatory proteins,” while the ozone “neutralizes pathogens (bacteria, viruses, fungi) and oxidizes toxins, turning them into inert substances the body can eliminate,” and describes the used filter’s contents as “a sludge-like residue often composed of cholesterol, lipids, dead pathogens, fungal metabolites, and heavy metals” [1]. Another clinic is more careful with its language, telling patients that “while there are claims that these filtered materials may contain heavy metals, microplastics, and parasites, current research is still investigating the exact composition of these by-products” [2]. That second framing, claims rather than findings, is the more accurate one, and this guide explains why.

The device: a dialysis-type membrane and what its pore size allows

EBO2 passes blood through a hemofilter, a hollow-fiber cartridge built the same way dialysis membranes are built: thousands of narrow, straw-like fibers bundled inside a cylindrical housing, with blood flowing through the inside of the fibers while the fiber wall itself does the separating. Membranes like this are manufactured to a specific pore size, sometimes described by the largest molecule they let through. Standard high-permeability membranes used in dialysis are designed to let small and some middle-sized molecules pass while retaining blood cells and larger proteins such as albumin; newer medium cutoff membranes use larger pores to allow bigger molecules through, at the cost of some albumin loss, a tradeoff nephrologists are still actively debating as they weigh clearing more of the molecules that build up in kidney failure against losing a protein the body needs to keep [3]. That engineering detail matters here because a membrane’s pore size sets a hard physical limit on what it can possibly capture, regardless of what marketing copy claims. A filter built to catch cells and larger debris cannot, by pore size alone, be assumed to also strip out something as small as a dissolved heavy metal ion unless that has actually been measured. Manufacturers choose a pore size for a purpose, and nothing published about the EBO2 device states what purpose its specific membrane was chosen for beyond supporting the gas exchange step.

What is documented in EBOO papers about filtrate contents

The peer-reviewed EBOO literature is thinner here than clinic marketing suggests. The one bench study of the device’s gas exchange component tested a saline solution, not blood, and measured how efficiently oxygen and ozone transferred into the fluid, reporting efficient gas transfer with minimal foreign surface contact and a negligible priming volume; it says nothing about what a filter captures from real blood in clinical use, because no blood, and no patient, was involved [4]. Those results describe how well the machine moves gas into a fluid, which is an engineering question, not a clinical one, and a study built to answer an engineering question cannot also answer a question about filtrate contents that it never measured. The foundational description of the EBOO technique explains that it combines continuous filtration with ozone exposure and argues this delivers a more controlled dose across more blood than batch methods, but this is rationale for the technique’s design, not a chemical analysis of filtrate [5]. The most directly relevant study measured urinary toxin markers, not the filter’s own contents: a single 88-year-old patient’s urinary mycotoxin, heavy metal, and other toxin markers declined across two series of EBOO treatments, except for one metal, nickel, which did not decline, and hemoglobin, which stayed largely unchanged [6]. That is a real, single-patient, independently authored finding worth taking seriously, but it measured what came out in urine after treatment, not what the filter cartridge itself trapped, and the authors themselves say it cannot establish causation or generalize beyond that one patient. No published study has taken a used EBO2 filter and chemically analyzed its contents, weighed the residue, or compared it against an untreated control filter run with the patient’s own blood.

What “toxins” means, and why the word does not name a molecule

“Toxins” is doing a lot of work in EBO2 marketing without naming anything specific. A heavy metal like lead is a toxin. So, in excess, is vitamin A, and so is water, taken in a large enough quantity in a short enough time. The word describes a category defined by dose and context, not a single measurable substance, and a claim that a filter “removes toxins” cannot be checked unless someone specifies which one, in what amount, and measures it before and after. When a clinic’s own language shifts from “toxins” to a more specific list, cholesterol, heavy metals, microplastics, fungal metabolites, that list becomes testable, and it is exactly the list that has not been tested for EBO2 in a controlled or even a chemically documented way beyond the one urinary case report above. A reader can use this as a practical filter of their own: any claim that names a specific substance and a specific amount can, in principle, be checked against a study; a claim that only names “toxins” cannot be checked at all, because there is nothing concrete to check.

Comparison with procedures that remove specific things

Some extracorporeal blood procedures do quantify what they remove. LDL apheresis, used mainly for children and adults with familial hypercholesterolemia and other patients with persistent high cholesterol despite medication, is reviewed at length in a 2024 American Heart Association scientific statement, which describes it as reducing LDL cholesterol and other specific lipoproteins, reducing proinflammatory and prothrombotic markers, and improving cardiovascular outcomes across multiple observational studies, all measured directly against a defined target and tracked at each session [7]. The statement describes LDL apheresis as an underused option precisely because it is a resource-intensive, specifically engineered procedure, not because its removal of cholesterol is in question. Plasmapheresis, covered in a companion guide on EBO2 versus plasmapheresis, separates and replaces a defined blood component, plasma, with the amount removed and replaced tracked precisely during the procedure. Both of these procedures can say, with a number attached, what came out, how much, and what happened to a patient’s blood values as a result. Nothing in the EBOO literature does that beyond the single urinary case report above, which measured urine rather than the filter’s own capture, in one patient, without a comparison to anyone who did not receive treatment.

The visible filtrate: why color and residue are not evidence

Clinics and patients both describe a strikingly discolored, sometimes sludgy residue left in the used filter cartridge, and it is often presented as visible proof that something harmful has been pulled from the blood. A hollow-fiber filter of this kind will catch ordinary cellular material, cell fragments, and proteins from any blood that passes through it, treated or not; capturing visible material is what a filter of this pore size does by design, not evidence of any specific toxin. A patient looking at a discolored cartridge cannot see a concentration, a molecule, or a wavelength; the eye is not a chemical assay, and two filters can look similarly dark for entirely different reasons. Without a chemical analysis of what is actually in that residue, comparing it before and after, or comparing a treated filter to an appropriate control, color and volume alone cannot distinguish “this filter caught something meaningful” from “this is what any filter looks like after blood passes through it.” A companion guide on whether EBO2 works covers the same reasoning as it applies to the treatment’s other claimed benefits. Ozone therapy itself is not FDA-approved for any condition, and federal regulation describes ozone as a toxic gas with no known useful medical application in specific, adjunctive, or preventive therapy [8].

Bottom line

EBO2 clinics describe the filter as removing toxins, cholesterol, heavy metals, and inflammatory material [1][2], but no published study has chemically analyzed or quantified what the filter cartridge itself captures [4][5]. The one relevant peer-reviewed finding measured urinary markers in a single patient, not the filter’s contents, and its own authors caution against generalizing from it [6]. The device’s pore size sets a physical limit on what it can plausibly trap [3], and procedures built specifically to remove a defined substance, like LDL apheresis, publish the numbers to prove it; EBO2 marketing has not [7]. Anyone weighing the claim against a visible residue in a used filter should ask what was actually measured, since that is a different question from what was seen. They can also ask the clinic whether any laboratory analysis of the filtrate exists beyond a visual description, and can review clinics offering the procedure with those two questions in mind before paying for a session on the strength of what the filter is said to remove.